TABLE 3.

Undergoing clinical trials investigating the efficacy, safety and tolerability of GLP‐1 RAs in the treatment of NAFLD

	Title	Conditions	Interventions	Characteristics	Primary outcome	Secondary outcome	Location
NCT03590626	Effect of dulaglutide on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease (D‐LIFT)	NAFLD T2DM	Dulaglutide Antidiabetic medicines	Randomized Phase: NA	Change in liver fat quantified by MRI‐PDFF	Changes in biochemical markers, LSM, CAP, etc	India
NCT03648554	Researching an effect of GLP‐1 agonist on liver steatosis (REALIST)	T2DM NASH	Dulaglutide Reinforced dietary monitoring	Randomized Phase 4	Regression of NASH without worsening of fibrosis	Changes in Kleiner score of fibrosis, fibrosis markers, and liver enzymes	France
NCT03987451	A research study on how semaglutide works in people with fatty liver disease and liver damage	NASH	Semaglutide Placebo	Randomized Phase 4	Relative change in liver stiffness measured by MRE	Relative change in LFC measured by MRI‐PDFF, NASH resolution, etc	United States
NCT03357380	A study on how semaglutide works on early stages of scar tissue in the liver assessed by pictures of the liver	Hepatobiliary disorders NAFLD	Semaglutide Placebo	Randomized Phase 1	Change in liver stiffness assessed by MRE	Change in liver stiffness assessed by MRE and in LFC by MRI‐PDFF, and proportion of subjects with at least 30% reduction in relative LFC.	Germany
NCT03884075	Nonalcoholic fatty liver disease, the hepatic response to oral glucose, and the effect of semaglutide (NAFLD HEROES)	NASH NAFLD	Semaglutide	Single‐group assignment Phase 2	Histological improvement（>=2 point decrease in NAFLD activity score） and clinical improvement	NA	United States
NCT02970942	Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with nonalcoholic steatohepatitis	Hepatobiliary disorders NASH	Semaglutide Placebo	Randomized Phase2	NASH resolution without worsening of fibrosis	liver fibrosis improvement, NAFLD activity score, etc	United States
NCT03987074	Safety, tolerability and efficacy of monotherapy and combination regimens in adults with nonalcoholic steatohepatitis (NASH)	NASH	Semaglutide Firsocostat Cilofexor	Randomized Phase 2	The number of treatment‐emergent adverse events and serious Adverse events (SAEs), and any grade ≥ 1 laboratory abnormality	NA	United States
NCT02654665	Comparing effects of liraglutide and bariatric surgery on weight loss, liver function, body composition, insulin resistance, endothelial function and biomarkers of nonalcoholic steatohepatitis (NASH) in obese Asian adults (CGH‐LiNASH)	NAFLD Weight Loss NASH	Liraglutide Lifestyle modification	Nonrandomized Phase 3	Improvement in NASH and reduction/normalization in transaminases and liver fat	NA	Singapore

Abbreviations: CAP, controlled attenuation parameter; LFC, liver fat content; LSM, liver stiffness measurement; MRE, magnetic resonance elastography; MRI‐PDFF, magnetic resonance imaging proton density fat fraction; NA, not applicable.